Program areas at SBF
The St. Baldrick's Foundation is the largest non-government funder of childhood cancer research grants in the u.s. These grants support every stage of research, from new discoveries to clinical trials, as well as the training of the next generation of pediatric oncology researchers. The Foundation also advocates for more effective policies and increased federal funding for childhood cancer research. The Foundation also makes disease-specific grants as well as grants aimed at multiple childhood cancers.in fy 2024, grants included the following categories: research grants -- 2-year hypothesis-driven research projects. (continued on schedule o. )consortium research grants -- large multi-institution research projects. Rfa awards -- large 3-year grants chosen via scientific review of applications solicited specifically for disease-specific research funded by donors and charity partners.fellowships -- early career researchers completing their pediatric oncology research training.scholars -- young investigator awards to enable early career scientists to continue research. Infrastructure grants -- support to open and conduct more clinical trials, to give children access to life-saving treatments closer to home.children's oncology group -- support disbursed to more than 200 institutions across north america and beyond, for the treatment of children on cog clinical trials.st. Baldrick's epicc team (empowering pediatric immunotherapies for childhood cancers) -- research to develop new immunotherapies for multiple childhood cancer types.research -two-year hypothesis-driven research grants focused on new and better treatments for childhood cancers.consortia -multi-year grants to researchers from multiple institutions who are collaborating on large research projects.international beneficiaries and domestic partners -- support for research in the us and other countries where St. Baldrick's fundraising events are held.in fye 2024, grants were awarded in the following categories:osteo sarcoma rfa award $1,350,000ewing sarcoma rfa award $500,000 fellowships $1,168,350scholars $2,801,458infrastructure $1,169,117children's oncology group $4,606,614st. Baldrick's epicc team $703,773research grants $1,630,000consortia $523,228international beneficiaries & domestic partners $287,498 the Foundation also plays a leading role in working with others to advance more effective policies and increased federal funding for childhood cancer research. We work with coalitions of other nonprofits supportive of childhood cancer and jointly trained volunteer advocates to educate elected officials, legislative staff, and federal agencies as to the needs of children with cancer and the work of the researchers endeavoring to save them. We led the effort to pass and later reauthorize the childhood cancer star act, and we have worked with advocates and the congressional childhood cancer caucus to secure full appropriations for star from congress every year since 2018. Similarly, we worked to secure continued funding for the childhood cancer data initiative and to ensure full appropriations each year since 2020. While the Foundation's advocacy expenses are reflected in form 990, schedule c, the funds generated for childhood cancer research as a result of these activities are not as they are provided by federal agencies to research institutions directly. These combined advocacy efforts have resulted in $80 million in additional federal funds for childhood cancer research annually. The Foundation advocates for legislation that expands access to care for childhood cancer patients, mitigates pediatric drug shortages, and increases opportunities for pediatric cancer drug development, working with partner organizations to support their important initiatives that serve the needs of kids with cancer. St. Baldrick's has been a strong supporter of the creating hope act, incentivizing companies to develop drugs specifically for childhood cancers, and the race for children act, requiring cancer drugs developed for adults to be studied for childhood cancers.